458 related articles for article (PubMed ID: 23141049)
1. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.
Oddens J; Brausi M; Sylvester R; Bono A; van de Beek C; van Andel G; Gontero P; Hoeltl W; Turkeri L; Marreaud S; Collette S; Oosterlinck W
Eur Urol; 2013 Mar; 63(3):462-72. PubMed ID: 23141049
[TBL] [Abstract][Full Text] [Related]
2. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
3. Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG.
Brausi M; Oddens J; Sylvester R; Bono A; van de Beek C; van Andel G; Gontero P; Turkeri L; Marreaud S; Collette S; Oosterlinck W
Eur Urol; 2014 Jan; 65(1):69-76. PubMed ID: 23910233
[TBL] [Abstract][Full Text] [Related]
4. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
[TBL] [Abstract][Full Text] [Related]
5. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Solsona E; Madero R; Chantada V; Fernandez JM; Zabala JA; Portillo JA; Alonso JM; Astobieta A; Unda M; Martinez-Piñeiro L; Rabadan M; Ojea A; Rodriguez-Molina J; Beardo P; Muntañola P; Gomez M; Montesinos M; Martinez Piñeiro JA;
Eur Urol; 2015 Mar; 67(3):508-16. PubMed ID: 25301758
[TBL] [Abstract][Full Text] [Related]
6. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
[TBL] [Abstract][Full Text] [Related]
7. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin.
Palou J; Sylvester RJ; Faba OR; Parada R; Peña JA; Algaba F; Villavicencio H
Eur Urol; 2012 Jul; 62(1):118-25. PubMed ID: 22101115
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
9. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
10. Should follow-up cystoscopy in bacillus Calmette-Guérin-treated patients continue after five tumour-free years?
Holmäng S; Ströck V
Eur Urol; 2012 Mar; 61(3):503-7. PubMed ID: 22119022
[TBL] [Abstract][Full Text] [Related]
11. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
[TBL] [Abstract][Full Text] [Related]
12. Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Marttila T; Järvinen R; Liukkonen T; Rintala E; Boström P; Seppänen M; Tammela T; Hellström P; Aaltomaa S; Leskinen M; Raitanen M; Kaasinen E;
Eur Urol; 2016 Aug; 70(2):341-7. PubMed ID: 27085624
[TBL] [Abstract][Full Text] [Related]
13. Maintenance bacillus Calmette-Guérin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence.
Ehdaie B; Sylvester R; Herr HW
Eur Urol; 2013 Oct; 64(4):579-85. PubMed ID: 23711538
[TBL] [Abstract][Full Text] [Related]
14. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Ojea A; Portillo J; Montesinos M; Gonzalez M; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
Eur Urol; 2011 Sep; 60(3):423-30. PubMed ID: 21621906
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy with intravesical bacillus Calmette-Guerin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer.
Muto S; Nakajima A; Horiuchi A; Inoue M; China T; Saito K; Isotani S; Hisasue S; Yamaguchi R; Ide H; Horie S
Jpn J Clin Oncol; 2013 Mar; 43(3):305-13. PubMed ID: 23303841
[TBL] [Abstract][Full Text] [Related]
16. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
[TBL] [Abstract][Full Text] [Related]
17. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
19. A Territory-wide Study Investigating the Dose and Efficacy of Different Bacillus Calmette-Guérin Strains in Patients with Intermediate- and High-risk Non-muscle-invasive Bladder Cancer.
Liu K; Zhao H; Chen X; Nicoletti R; Vasdev N; Chiu PK; Ng CF; Kawada T; Laukhtina E; Mori K; Yanagisawa T; D'Andrea D; von Deimling M; Albisinni S; Krajewski W; Pradere B; Soria F; Moschini M; Enikeev D; Shariat S; Kamat A; Giannarini G; Teoh JY;
Eur Urol Oncol; 2024 Jun; 7(3):438-446. PubMed ID: 37827948
[TBL] [Abstract][Full Text] [Related]
20. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
Ojea A; Nogueira JL; Solsona E; Flores N; Gómez JM; Molina JR; Chantada V; Camacho JE; Piñeiro LM; Rodríguez RH; Isorna S; Blas M; Martínez-Piñeiro JA; Madero R;
Eur Urol; 2007 Nov; 52(5):1398-406. PubMed ID: 17485161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]